FDA
-
-
-
-
-
-
-
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
-
-
-
-
-
-
-
Palvella Therapeutics moves to NASDAQ Global Market
-
-
-
-
-
-
-
Palvella to present QTORIN rapamycin study results at vascular congress
-
-
-
-
-
-
-
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Palvella hires Jennifer McDonough as market access VP
-
-
-
-
-
-
-
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Or
-
-
-
-
-
-
-
Palvella Therapeutics reports positive phase 3 trial results for rare disease
-
322,976 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

